Literature DB >> 7263127

Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes.

E Cotlier.   

Abstract

The prevalence of cataracts is significantly lower in patients with rheumatoid arthritis receiving aspirin (mean of 2,700 mgs daily for an average of 10.4 years) as compared to the matched population not receiving aspirin. Similarly, fewer cataracts were found among a population with diabetes and rheumatoid arthritis receiving aspirin (mean of 2,340 mgs daily for an average of 8.8 years) as compared to the matched population on no aspirin. The effects of aspirin on cataract formation may result from 1) lowering of plasma tryptophan levels and increased excretion of tryptophan metabolites, 2) inhibition of aldose reductase and sorbitol formation in the diabetic lens, 3) inhibition of tryptophan or kynurenine binding to lens protein.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7263127     DOI: 10.1007/BF00130701

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  21 in total

1.  Metabolism of tryptophan in rheumatoid arthritis.

Authors:  I M BETT
Journal:  Ann Rheum Dis       Date:  1962-03       Impact factor: 19.103

2.  Effects of acetylsalicylic acid on serum protein binding and metabolism of tryptophan in man.

Authors:  H G Smith; C Lakatos
Journal:  J Pharm Pharmacol       Date:  1971-03       Impact factor: 3.765

Review 3.  The sorbitol pathway and the complications of diabetes.

Authors:  K H Gabbay
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

4.  Photo-oxidation of lens proteins by sunlight in the presence of fluorescent derivatives of kynurenine, isolated from the human lens.

Authors:  R Van Heyningen
Journal:  Exp Eye Res       Date:  1973-10-24       Impact factor: 3.467

5.  Hypoglycemic activity and chemical structure of the salicylates.

Authors:  V Fang; W O Foye; S M Robinson; H J Jenkins
Journal:  J Pharm Sci       Date:  1968-12       Impact factor: 3.534

6.  Inhibition of lens aldose reductase by flavonoids--their possible role in the prevention of diabetic cataracts.

Authors:  S D Varma; J H Kinoshita
Journal:  Biochem Pharmacol       Date:  1976-11-15       Impact factor: 5.858

7.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality.

Authors:  A Linos; J W Worthington; W M O'Fallon; L T Kurland
Journal:  Am J Epidemiol       Date:  1980-01       Impact factor: 4.897

8.  Plasma tryptophan in humans with diabetic and senile cataracts.

Authors:  E Cotlier; Y R Sharma; J Zuckerman; J Pucklin; B Teasley; J Irvine
Journal:  Exp Eye Res       Date:  1981-09       Impact factor: 3.467

9.  Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects.

Authors:  P Micossi; A E Pontiroli; S H Baron; R C Tamayo; F Lengel; M Bevilacqua; U Raggi; G Norbiato; P P Foà
Journal:  Diabetes       Date:  1978-12       Impact factor: 9.461

10.  Altering the course of cataracts in diabetic rats.

Authors:  S Fukushi; L O Merola; J H Kinoshita
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-03       Impact factor: 4.799

View more
  4 in total

Review 1.  Aspirin and the elderly. Current status.

Authors:  C Silagy
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

2.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

Review 3.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

4.  Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats.

Authors:  Qiong Shi; Hong Yan; Ming-Yong Li; John J Harding
Journal:  Mol Vis       Date:  2009-10-21       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.